IP Library Granted Patent US 8,642,075
Granted Patent B2
US 8,642,075 · App. 13/666,420 · Granted Feb 4, 2014

Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,075
App. No.
13/666,420
Granted
Feb 4, 2014
Kind
B2
Abstract

A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Claims (20)

1. An aerosolized composition for the treatment of a pulmonary infection comprising free aminoglycoside in an amount effective to provide immediate bactericidal activity against the pulmonary infection and liposomal encapsulated aminoglycoside in an amount effective to provide sustained bactericidal activity against the pulmonary infection, wherein the lipid component of the liposome consists of electrically neutral lipids, and the aerosolized composition comprises droplets of an aqueous solution or suspension.

2. The aerosolized composition of claim 1 , wherein the aminoglycoside is amikacin.

3. The aerosolized composition of claim 1 , wherein the aminoglycoside is gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin or paromomycin.

4. The aerosolized composition of claim 1 , wherein the liposomal encapsulated aminoglycoside comprises a mixture of unilamellar vesicles and multilamellar vesicles.

5. The aerosolized composition of claim 1 , wherein the electrically neutral lipids comprise an electrically neutral phospholipid and a sterol.

6. The aerosolized composition of claim 1 , wherein the electrically neutral lipids comprise a phosphatidylcholine and a sterol.

7. The aerosolized composition of claim 1 , wherein the electrically neutral lipids comprise a phosphatidylcholine and cholesterol.

8. The aerosolized composition of claim 1 , wherein the electrically neutral lipids comprise dipalmitoylphosphatidylcholine (DPPC) and a sterol.

9. The aerosolized composition of claim 1 , wherein the electrically neutral lipids comprise dipalmitoylphosphatidylcholine (DPPC) and cholesterol.

10. The aerosolized composition of claim 1 , wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:100 and about 100:1.

11. The aerosolized composition of claim 1 , wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:10 and about 10:1.

12. The aerosolized composition of claim 1 , wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:2 and about 2:1.

13. The aerosolized composition of claim 2 , wherein the liposomal encapsulated amikacin comprises unilamellar and multilamellar vesicles.

14. The aerosolized composition of claim 2 , wherein the electrically neutral lipids comprise a phosphatidylcholine and a sterol.

15. The aerosolized composition of claim 2 , wherein the electrically neutral lipids comprise a phosphatidylcholine and cholesterol.

16. The aerosolized composition of claim 2 , wherein the electrically neutral lipids comprise a dipalmitoylphosphatidylcholine (DPPC) and a sterol.

17. The aerosolized composition of claim 2 , wherein the electrically neutral lipids comprise a dipalmitoylphosphatidylcholine (DPPC) and cholesterol.

18. The aerosolized composition of claim 2 , wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:100 and about 100:1.

19. The aerosolized composition of claim 2 , wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:10 and about 10:1.

20. The aerosolized composition of claim 2 , wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:2 and about 2:1.

Assignments (8)
PATENT SECURITY AGREEMENT Recorded Oct 20, 2022
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061735/0875 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Oct 19, 2022
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 061727/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY STREET ADDRESS PREVIOUSLY RECORDED AT REEL: 038947 FRAME: 0075. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 1, 2016
From: TRANSAVE, LLC
To: INSMED INCORPORATED
Reel/Frame 039235/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2016
From: TRANSAVE, LLC
To: INSMED INCORPORATED
Reel/Frame 038988/0034 →
MERGER Recorded Jun 22, 2016
From: TRANSAVE, INC.
To: TRANSAVE, LLC
Reel/Frame 038988/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2016
From: WEERS, JEFF
To: TRANSAVE, INC.
Reel/Frame 038987/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2016
From: WEERS, JEFF
To: TRANSAVE, INC.
Reel/Frame 038987/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2013
From: WEERS, JEFF
To: INSMED INCORPORATED
Reel/Frame 030091/0118 →